These are heady times for Thomas I.H. Dubin, of Alexion Pharmaceuticals in Cheshire.
After 15 years of development and trials, the company is set to release in 2007 its first commercial product, Soliris, a groundbreaking drug designed to treat a type of severe, fatal anemia known as nocturnal paroxysmal hemoglobinuria (PNH).
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
